Onglyza (Saxagliptin HCl) Patent Expiration, LOE Window & CMS Spending

Onglyza (Saxagliptin HCl) by AstraZeneca: FDA Orange Book LOE 2028-11-30, 3 AB generics, $5.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstraZeneca
FDA Application & PathwayN022350 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2028-11-30
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$5.9M
2024 Medicare Part D Spend$3.3M
2024 Medicaid Spend$2.6M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.